Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
Dummer, R., Gyorki, D. E., Hyngstrom, J., Berger, A. C., Conry, R., Demidov, L., Sharma, A., Treichel, S. A., Radcliffe, H., Gorski, K. S., Anderson, A., Chan, E., Faries, M., Ross, M. I.
Published in Nature medicine (01.10.2021)
Published in Nature medicine (01.10.2021)
Get full text
Journal Article
Age‐related endothelial dysfunction in human skeletal muscle feed arteries: the role of free radicals derived from mitochondria in the vasculature
Park, S.‐Y., Kwon, O. S., Andtbacka, R. H. I., Hyngstrom, J. R., Reese, V., Murphy, M. P., Richardson, R. S.
Published in Acta Physiologica (01.01.2018)
Published in Acta Physiologica (01.01.2018)
Get full text
Journal Article
Use of Adjuvant Radiation Therapy in Node-positive Melanoma in the United States
Orton, A, Hyngstrom, J, Andtbacka, R.H.I, Bowles, T, Grossmann, K, Khong, H, Grossman, D, Bowen, G, Hitchcock, Y.J, Bilimoria, K, Suneja, G
Published in International journal of radiation oncology, biology, physics (01.11.2015)
Published in International journal of radiation oncology, biology, physics (01.11.2015)
Get full text
Journal Article
522 Associations between influenza vaccine and immunotherapy outcomes in metastatic melanoma patients
Erickson, M., Truong, A., Boucher, K., Hyngstrom, J.
Published in Journal of investigative dermatology (01.05.2021)
Published in Journal of investigative dermatology (01.05.2021)
Get full text
Journal Article
LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)
Dummer, R., Gyorki, D., Hyngstrom, J., Berger, A., Conry, R., Demidov, L., Ning, L., Lawrence, T., Faries, M., Ross, M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1346PComparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma
Moser, J, Wei, G, Colonna, S, Grossmann, K F, Patel, S, Hyngstrom, J
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma
Moser, J., Wei, G., Colonna, S., Grossmann, K.F., Patel, S., Hyngstrom, J.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1346P - Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma
Moser, J., Wei, G., Colonna, S., Grossmann, K.F., Patel, S., Hyngstrom, J.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
Patel, S., Othus, M., Wright, P., Hyngstrom, J., Lao, C.D., Truong, T-G., Chandra, S., Kendra, K., Devoe, C., Hegde, A., Mangla, A., Lowe, M., Buchbinder, E., Kirkwood, J.M., Sharon, E., Korde, L., Moon, J., Sondak, V.K., Ribas, A., Prieto, V.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
Patel, S., Othus, M., Prieto, V., Lowe, M., Buchbinder, E., Chen, Y., Hyngstrom, J., Lao, C.D., Truong, T-G., Chandra, S., Kendra, K., Devoe, C., Hedge, A., Mangla, A., Sharon, E., Korde, L., Moon, J., Sondak, V., Ribas, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma
Dummer, R., Gyorki, D.E., Hyngstrom, J., Berger, A., Conry, R., Demidov, L., Sharma, A., Treichel, S.A., Gorski, K., Anderson, A., Faries, M., Ross, M.I.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
LBA66 - Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma
Dummer, R., Gyorki, D.E., Hyngstrom, J., Berger, A., Conry, R., Demidov, L., Sharma, A., Treichel, S.A., Gorski, K., Anderson, A., Faries, M., Ross, M.I.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
LBA66Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma
Dummer, R, Gyorki, D E, Hyngstrom, J, Berger, A, Conry, R, Demidov, L, Sharma, A, Treichel, S A, Gorski, K, Anderson, A, Faries, M, Ross, M I
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
Dummer, R., Gyorki, D. E., Hyngstrom, J., Berger, A. C., Conry, R., Demidov, L., Sharma, A., Treichel, S. A., Radcliffe, H., Gorski, K. S., Anderson, A., Chan, E., Faries, M., Ross, M. I.
Published in Nature medicine (04.10.2021)
Published in Nature medicine (04.10.2021)
Get full text
Journal Article